Real-World study examines Isavuconazole's effectiveness against deadly fungal infections

NCT ID NCT04550936

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at medical records of 307 adults in five European countries who were treated with the antifungal drug isavuconazole for serious fungal infections (invasive aspergillosis or mucormycosis). Researchers tracked how well the drug worked (clinical, radiological, and lab responses) and any side effects over 24 weeks. Since this was an observational study, patients received standard care as decided by their doctors, and no extra drugs were provided.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Isavuconazole (Cresemba)
What this could lead to: If the results confirm isavuconazole is effective and safe in routine care, it could reinforce its use as a treatment option for these serious fungal infections.
What could go wrong: This is an observational study, not a controlled trial, so it can't prove cause and effect. The results may be influenced by differences in patient care and underlying health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE ASPERGILLOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive aspergillosis Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE ASPERGILLOSIS MUCORMYCOSIS

Contacts and locations

Locations

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

Turin, Piedmont, 10126, Italy
CHU de Limoges

Limoges, 87042, France
Cambridge University Hospitals NHS Foundation Trust

Cambridge, CB2 0QQ, United Kingdom
Comprehensive Cancer Center Ulm (CCCU)

Ulm, 89081, Germany
Fundació Clínic Per A La Recerca Biomèdica

Barcelona, 08036, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Marques de Valdecilla

Santander, 39011, Spain
Institut de Cancérologie

Strasbourg, 67033, France
King'S College Hospital Nhs Foundation Trust

London, SE5 9RS, United Kingdom
Klinikum rechts der Isar Technische Universität München

Munich, 81675, Germany
Paris University

Paris, 75015, France
University Hospital Miguel Servet

Zaragoza, 50009, Spain
University Hospital of Cologne

Cologne, 50937, Germany
Universitätsklinik Frankfurt

Frankfurt, 60590, Germany
Vall d'Hebron University Hospital

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.